RallyBio is steering around more tight corners as it announces a further 40% reduction in staffers just weeks after ...

GSK has shared the data behind its phase 3 liver disease win, revealing patients on linerixibat reported reductions in ...

Takeda has shot down candidates acquired in its $525 million Maverick Therapeutics takeover, blowing a hole in its oncology R ...

California investment firm Vivo Capital has secured $740 million in commitments to be aimed at preclinical- and ...

Charles River CEO James Foster had previously attributed the 2024 revenue dip to decreased demand from biopharma clients. In ...

Roche is rolling out a new diagnostic test to help assess hidden liver fibrosis in patients showing signs of metabolic ...